Regeneron Reevaluates Bispecific Antibody Strategy Following Fatalities
Regeneron is reassessing its PSMA/CD28 bispecific antibody development in prostate cancer after two patient deaths occurred during a combination trial with Libtayo. The company has halted patient enrollment in the trial due to the emerging safety profile, including the deaths.